Clonal Architecture of ASXL1-mutated Myelofibrosis

Sponsor
University Hospital, Angers
Study ID
NCT05710211
Status
Recruiting
Apply to this trial

Conditions

  • Myelofibrosis

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Clonal architecture determination — BIOLOGICAL
    Biological: * Determination of clonal architecture by sorting of circulating CD34 positive cells followed by cell culture and colony genotyping and/or single-cell DNA-sequencing * Secondary outcome: transcriptomic study by RNA-sequencing

Study Details

Prospective study to decipher the clonal architecture of ASXL1-mutated primary and secondary myelofibrosis and its impact on prognosis

Key Dates

First listed
Feb 2, 2023
Start date
Apr 24, 2023
Status verified
Mar 2026
Primary completion
Apr 23, 2027
Completion
Apr 23, 2031

Study Design

Enrollment
50 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
OTHER

Arms

  • Experimental: CLONEMF cohort

Primary Outcome Measure

Identify subgroups of ASXL1-mutated myelofibrosis based on clonal architecture data [ Time Frame: 24 months ]

Central Contacts

Related Studies